Liquidia Corporation

Update in progress

LQDA (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

Liquidia Corporation is a biopharmaceutical company focused on developing, manufacturing, and commercializing therapies for rare cardiopulmonary diseases in the United States. Its lead candidate YUTREPIA is an inhaled treprostinil for PAH and PH-ILD; Remodulin is a treprostinil injection for IV/SC infusion; L606 is a liposomal treprostinil in phase III for PAH and PH-ILD. The company also offers PRINT technology and licenses with Pharmosa Biopharm, Vectura, UNC Chapel Hill, GlaxoSmithKline, Alcon, and Sandoz. Founded in 2004, based in Morrisville, NC.

Company score

Sentiment: 0.14; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.17; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.13; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.02; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.08; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive